What Is Compounded Tirzepatide?

Tirzepatide is a medication that acts on two different hormone receptors:

• GLP-1 (glucagon-like peptide-1)
• GIP (glucose-dependent insulinotropic polypeptide)

Both are naturally occurring hormones involved in the body's response to food.

GLP-1 and GIP signaling can influence appetite, feelings of fullness, insulin secretion, and blood sugar regulation.

Because tirzepatide activates both pathways, it is sometimes described as a dual GIP/GLP-1 receptor agonist.

This dual mechanism is one of the major differences between tirzepatide and medications such as semaglutide, which primarily target the GLP-1 receptor.

Tirzepatide may help with weight loss in several ways. It can:

• Lower appetite
• Help you feel full longer
• Reduce how much you eat
• Support healthy blood sugar levels
• Make it easier to eat fewer calories

Tirzepatide has been studied in people with obesity or overweight.

In a large study called SURMOUNT-1, more than 2,500 adults took tirzepatide for 72 weeks. Depending on the dose, participants lost an average of about 15% to 20.9% of their body weight.

Compounding means preparing a medication for a patient's specific needs.

Compounded medications are used in many areas of healthcare, not just weight management.

A healthcare provider may prescribe a compounded medication when they believe a customized treatment is appropriate and the prescription meets applicable requirements.

Some compounded medications are prepared by 503A compounding pharmacies for individual patients. Others are prepared by 503B outsourcing facilities, which follow a different set of federal requirements.

Compounded medications are prepared and regulated differently from commercially manufactured medications.

Compounded tirzepatide is tirzepatide-based prescription treatment prepared by a compounding pharmacy according to a prescription from a licensed healthcare provider.

Depending on the pharmacy and prescription, the medication may be prepared in different concentrations or dispensing formats.

For example, compounded tirzepatide is commonly dispensed in a multidose vial that patients use with an appropriate syringe.

The exact formulation, concentration, instructions, and availability can vary depending on the dispensing pharmacy and the patient's prescription.

That's why patients should always follow the instructions provided specifically with their medication.

Compounding is intended to support individualized patient care when a compounded prescription is clinically appropriate and permitted under applicable requirements.

There can be situations where a healthcare provider determines that a patient's needs are not met by an available commercially manufactured product.

Depending on the patient and applicable compounding rules, this could involve considerations such as:

• A particular prescribed concentration
• An alternative dosage form
• A formulation tailored to an identified clinical need
• An allergy or sensitivity to certain ingredients in an available product
• Other patient-specific medical considerations

Whether compounded treatment is appropriate should be determined by a licensed healthcare provider rather than by the patient alone.

No. Compounded tirzepatide is not FDA-approved Zepbound or Mounjaro.

Zepbound and Mounjaro are commercially manufactured tirzepatide products made by Eli Lilly.

Compounded tirzepatide is separately prepared by registered pharmacies pursuant to applicable compounding requirements.

While the treatments may involve tirzepatide, compounded medications can differ in areas such as:

• Concentration
• Packaging
• Dosage form
• Administration instructions
• Dispensing format

Equivalent safety and effectiveness to Zepbound or Mounjaro have not been established for compounded tirzepatide. Differences are not limited to packaging or dosing instructions.

Patients should rely on the label and instructions accompanying their specific prescription.

Tirzepatide treatment is generally started at a lower dose and gradually increased based on the treatment plan and patient response.

Gradual dose escalation can help the body adjust to treatment and may improve gastrointestinal tolerability.

With compounded tirzepatide, understanding the medication's concentration is especially important.

Patients using a multidose vial may receive instructions telling them how much medication to draw into a syringe.

Before beginning treatment, patients should understand:

• Their prescribed dose
• Their medication's concentration
• How much to draw into the syringe
• How frequently to administer it
• How to properly store the medication
• When their dose may change
• Who to contact if they have dosing questions

Never copy another patient's dosing instructions, even if they're also taking tirzepatide.

Where a compounded prescription comes from is an important part of treatment.

Patients should know which pharmacy is preparing and dispensing their medication.

Depending on the type of facility, compounding pharmacies and outsourcing facilities are subject to different federal and state requirements governing areas such as pharmacy practice, manufacturing standards, dispensing, labeling, and quality.

Patients should also receive clear labeling and instructions with their prescription.

A well-structured telehealth program should be transparent about where medications are being dispensed and provide patients with a way to ask questions about their prescription.

Like other medications affecting incretin pathways, tirzepatide can cause gastrointestinal side effects.

Commonly reported effects include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal discomfort
• Decreased appetite

In the SURMOUNT-1 clinical trial, gastrointestinal symptoms were the most frequently reported adverse events. Most were mild to moderate and occurred primarily while doses were being increased.

This is one reason gradual dose escalation and communication with a healthcare provider are important parts of treatment.

Medical weight-loss treatment should involve more than simply ordering medication online.

A well-structured program should make it clear:

• Who is evaluating you
• Who is prescribing your medication
• Which pharmacy is filling the prescription
• What dose and concentration you've been prescribed
• How to administer the medication
• How to store it
• How dose adjustments are handled
• How to contact your healthcare team
• What follow-up care is available

Patients should feel comfortable asking questions throughout treatment.

Compounded medications are not individually reviewed and approved by the FDA in the same manner as commercially manufactured medications.

This doesn't mean that pharmaceutical compounding itself is prohibited.

Compounding has an established role in healthcare and is governed by federal and state requirements. However, compounded medications are prepared through a different regulatory pathway than commercially manufactured products such as Zepbound and Mounjaro.

Whether compounded tirzepatide may be prescribed and prepared also depends on current federal and state compounding requirements.

Studies of an approved tirzepatide product do not establish the safety, effectiveness or quality of a compounded formulation. Ask whether an advertised outcome was actually studied with the product you would receive rather than assuming brand research validates it.

FDA: unapproved GLP-1 concerns

Compounded tirzepatide is a prescription treatment prepared by a qualified compounding pharmacy or outsourcing facility when clinically appropriate and permitted under applicable requirements.

Tirzepatide works through both GIP and GLP-1 receptors, giving it a dual mechanism that has been extensively studied for metabolic health and weight management.

Compounded prescriptions may differ in concentration, dispensing format, and administration instructions, which makes clear communication between the patient, healthcare provider, and pharmacy particularly important.

Patients considering tirzepatide should receive an appropriate medical evaluation, understand exactly what they have been prescribed, and have access to ongoing clinical support throughout treatment.

At Luma, eligible patients are evaluated by a licensed healthcare provider who can determine whether a treatment option is appropriate based on their medical history, goals, and individual needs. Medication availability and treatment options depend on clinical appropriateness and applicable state and federal requirements.